The Sputnik V vaccine demonstrates the best safety record in the Argentine province of Buenos Aires

The Russian Direct Investment Fund (RDIF, the sovereign wealth fund of the Russian Federation) releases data from the Ministry of Health of the province of Buenos Aires ( Argentina ) according to which the Russian vaccine against the Sputnik V coronavirus has the best safety record among vaccines used in the province.

Data for the period December 29, 2020 to June 3, 2021 show that, with 2.8 million doses administered, Sputnik V has the lowest rate of serious adverse events. The complete study by the Ministry of Health of the province of Buenos Aires can be found at:

Kirill Dmitriev , CEO of the Russian Direct Investment Fund (RDIF) , said:

“World experience shows that Sputnik V has the best safety profile compared to other vaccines. This is confirmed by international data from national and regional ministries of health in several countries in different regions of the world where the Sputnik V vaccine is successfully used to protect the health of citizens.”

The Sputnik V vaccine has the following important advantages:

  • Vaccine efficacy is 97.6% based on analysis of coronavirus incidence data in Russians vaccinated with the two vaccine components from December 5, 2020 to March 31, 2021.
  • The Sputnik V vaccine was developed based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and which have been known to mankind for millennia.
  • The Sputnik V vaccine uses two different vectors for two injections during the vaccination process, which creates stronger immunity compared to vaccines that use the same delivery mechanism for both injections .
  • The safety, efficacy, and absence of long-term adverse effects of adenovirus vaccines have been proven in more than 250 clinical studies over two decades.
  • Sputnik V does not cause serious allergies.
  • The storage temperature of the “Sputnik V” is + 2 to + 8 degrees Celsius, which allows it to be stored in a conventional refrigerator without the need to invest in additional infrastructure in the refrigeration chain.
  • Sputnik V costs less than $10 per injection, making it affordable for the entire world.

The Russian Direct Investment Fund (RDIF)  was founded in 2011 to invest in equity capital of companies primarily in Russia, together with major foreign financial and strategic investors. The fund acts as a catalyst for direct investment in the Russian economy. At present, RDIF has a successful track record of jointly implementing more than 80 projects with foreign partners with a total volume of over 2 trillion rubles, covering 95% of Russian regions. RDIF portfolio companies employ more than 800,000 employees and their annual revenue is 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from 18 countries totaling more than $40billion. More information can be found on the website:

Contact for further information:
Alexey Urazov
Russian Direct Investment Fund
Director of External Communications
Mobile: +7 915 312 76 65
E-mail: [email protected]

Logo –

SOURCE Russian Direct Investment Fund (RDIF)

Related Links

SOURCE Russian Direct Investment Fund (RDIF)

Leave a Reply

Your email address will not be published. Required fields are marked *